在QTc间隔和与 osimertinib 治疗相关的其他参数的电心图变化
Yilin Pan1,2, Kexin Peng1, Yichuan Jiang3
1Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Changchun, China.
Frontiers in oncology
|July 3, 2025
概括
对EGFR突变NSCLC的奥西默蒂尼布治疗显著延长QT间隔,表明需要仔细的心脏监测. 这一发现对于管理肺癌患者潜在的心脏毒性至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥西默提尼布是EGFR突变非小细胞肺癌 (NSCLC) 的关键治疗方法.
- 这种药物与心脏毒性有关,特别是QT间隔延长.
- 增加奥西默提尼布的使用需要更深入地了解其对心脏的影响.
研究的目的:
- 评估EGFR突变NSCLC患者的心电图 (ECG) 变化,这些患者接受了osimertinib治疗.
- 评估奥西默蒂尼布对各种心电图参数的影响,重点关注QT间隔延长.
主要方法:
- 对41名接受 osimertinib.com 治疗的 NSCLC 患者进行了回顾性,单中心的研究.
- 治疗前后对心电图记录的分析.
- 手动计算和评估心率,PR间隔,QRS持续时间,QRS轴和QT间隔.
主要成果:
- 观察到巴塞特 (P < 0.0001) 和弗里德里西亚 (P = 0.0002) 的QTc间隔显著延长.
- 在统计学上,QT间隔的延长是显著的 (麦克纳马测试P = 0.0039).
- 没有注意到心率,PR间隔或QRS持续时间的显著变化.
结论:
- 奥西默蒂尼布治疗导致EGFR突变NSCLC患者的QT间隔显著延长.
- 严格的心电图监测对于减轻与 osimertinib 相关的心脏毒性风险至关重要.
- 这项研究强调了在接受EGFR-TKI治疗的NSCLC患者心脏监测的重要性.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
Electrocardiogram
3.3K
An electrocardiogram (ECG or EKG) is a critical diagnostic tool that records the electrical signals produced by the heart during each heartbeat. This recording is achieved through electrodes placed strategically on the arms, legs, and chest. The electrocardiograph amplifies these signals and produces 12 distinct tracings, offering a comprehensive understanding of the heart's electrical activity.
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
3.3K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
170
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
170
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Correlation between ECG and Cardiac Cycle
8.5K
The electrical signals recorded on an electrocardiogram (ECG) occur before the mechanical processes of contraction and relaxation during the cardiac cycle.
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...
8.5K


